DEPARTMENT OF HEALTH SERVICES

Division of Public Health F-44000 (10/2018)

Pharmacy:

☐ Skywalk ☐ Other, List

TUBERCULOSIS DISEASE INITIAL REQUEST FOR MEDICATION

STATE OF WISCONSIN

s. 252.10 (7), Wis. Stats. Wisconsin Tuberculosis Program Telephone: 608-261-6319

Page 1 of 2

Fields marked with an (*) asterisk are required. Please complete patient information on reverse side.

Submit completed form to the Local Health Department.

Submit completed form to the Local Health Department.										
SUBMIT COM Local Health		-				LHD Fax Number				
*NAME –Pa	tient (Las	t, First, Middle Initial)		*Date of Birth (mm/dd/yyyy)						
*Address (S	treet or R	ural Route)				*Telephone Number				
*City		*Zip Code *		LHD/Clinic to Send Meds		Other contact, as needed				
*Sex	*Race *Ethnicity Hispanic Non-Hispanic		*Weight	t	*Prescription Insurance Provider & Insurance No					
*NAME – Clinician (Print clearly) NAME - Hospital/Clinic/Facility										
*Address (Street, City, State, Zip code) *Telephone Number										
		DERS (Check mg/kg for patients with								
Medication	Do	Dose		Frequency		Duration of Therapy				
Isoniazid (II	NH)	300 mg 🗌 mg 🔲 m	g/kg [☐ Da	ily 🗌 Other	6 mo				
(Generic only) 10-15 mg/kg infants + children; 5 mg/kg up to 100 lb/45.5 kg adults; 300 mg maximum daily all others										
Rifampin										
(Generic or	ily) ¹⁰⁻²	20 mg/kg infants + children; 10 mg/kg up	to 100 lb/-	45.5 kg	adults; 600 mg m	aximum daily all others				
Ethambuto	I 🗆	800 mg	g — -		7.00					
(Generic or		Daily Dther 2 mo 6 mo Other Other								
,	<i>3</i> /	ng/kg infants + children; 40-55 kg, 800 m	ng; 56 – 75	kg, 12	00 mg; 76 – 90 kg,	1600 mg; long term EMB=15mg/kg				
Pyrazinamide ☐ 1000 mg ☐ 1500 mg ☐ 2000 mg ☐ Daily ☐ Other ☐ 2 mo ☐ 6 mo ☐ Other										
	30-4	10 mg/kg infants + children; 40 – 55 kg, 1	1000 mg; 5	6 – 75 I	kg, 1500 mg; 76 – 9	00 kg, 2000 mg; long-term PZA=25mg/kg				
☐ Vitamin		50 mg/day when on INH				no Other				
■ Multivita		One tab daily								
	clude Vitam	in $D \ge 400 IU (10 mcg)$ for infants $0 - 12 m$	onths, 600	IU (15	mcg) for children an	d adults; for the duration of the prescription.				
Other:										
Other:										
Standard of care: All medications are given together under directly observed therapy (DOT). Medications are administered seven (7) days per week for at least the first two weeks of therapy. Then medications may be administered five (5) days per week by DOT, with the remaining two doses self-administered over the weekend. Medications for those expected to gain weight during therapy are written as mg/kg; the nurse will weigh the person weekly and drug dosage will be adjusted to maintain the mg/kg dose as closely as can be measured. Adjustments to dose, frequency, and duration of therapy are common and depend upon the individual patient's disease and response to therapy. MONITORING ORDERS 1. Beginning with the third week of therapy, collect one sputum sample weekly and send to WSLH for smear and culture. 2. Assess the patient at least weekly for side effects and medication toxicity. Hold medications and call clinician if present.										
SIGNATURE										
*SIGNATUR	E – Clinici		* Date Prescription Ordered:							
WEDSS Disease Incident Number				Ship medication to:						

WEDSS Disease Incident No. **Patient Name:**

PATIFNT	INFORMATION	(*Required)
		(i (Cyulleu)

A. *Tests:											
1. T-Spot™ blood assay:	T-Spot™ blood assay: Date Drawn: Results: □Positive □Negative □Indeterminate □In										
2. Quantiferon™ (QFT) b	lood assay: Date	Drawn:	Results: Po	ositive	determinate						
OFT Numeric results: Nil	IU/mL	TB Nil	IU/mL Mitogen _	IU/mL							
3. Tuberculin Skin Test:	Date Applied:		_Date Read:	Results (induration	only) mm						
4. Specime		Sample Date	Results								
(Sputum or	BAL)		Smear	PCR	Culture						
Other:											
5. Sputum/other culture:	Specimen sou	ırce:		Date positive culture repo	orted						
B. *Is patient symptomatic? (check all that apply)											
☐ Fever ☐ Night s	weats 🗌 Cough > 3	3 weeks □	Sputum ☐Blood in sputu	um 🗌 Weight loss							
Other	☐ Other										
C. *Reason for referral	for treatment: (che	ck all that a	pply)								
Suspect TB disease	• ☐ Confirmed TB	disease									
			se, if known								
D. *Chest X-Ray or CT:	(Include copy of che	st x-ray and/		<u> </u>							
	Date		Results:	☐ Normal ☐ Abnormal	I ☐ Cavitary						
E. *Prior treatment for t ☐ NO ☐ YES Please											
F. Risk factors for adve	erse reactions or no	on-adherenc	e?								
Specify											
G. *Risk factors for dru	•	•	,	11 7/							
			ry of birth:								
Liver impairment (he	patitis, alcohol use,	drug use, oth	her)						
☐ Diabetes: ☐ Insuli	n-dependent	al hypoglyce	mic Poorly-controlled	d							
☐ Immunosuppressed	? Explain:										
☐ Population risk facto	or (travel outside US,	jail or prison	in other state/country)								
H. *Baseline blood test	s										
HIV	Date	Result									
ALT/AST	Date	Result									
CBC w/platelets	Date	Result									
T. BIL	Date	Result									
S. Creatinine	Date	Result									
Uric Acid	Date	Result									

Date

Other:

References
Treatment of tuberculosis. *MMWR Recommendations and Reports*. 52:RR-11. June 20, 2003. Red Book. American Academy of Pediatrics. 29th Edition. 2012.

Result